Associated Papers
Overexpression of P-glycoprotein and MRP-1 are pharmacogenomic biomarkers to determine steroid resistant phenotype in childhood idiopathic nephrotic syndrome.
Prasad N et al.
The Pharmacogenomics Journal, 2021
Genetic Diversity in Drug Transporters: Impact in African Populations.
Rajman I et al.
Clinical and Translational Science, 2020
Lack of association between ABCB1 gene polymorphisms and pharmacoresistant epilepsy: an analysis in a western Chinese pediatric population.
Dong L et al.
Brain Research, 2011
Placental P-glycoprotein and breast cancer resistance protein: influence of polymorphisms on fetal drug exposure and physiology.
Hutson JR et al.
Placenta, 2010
Emerging new technologies in Pharmacogenomics: rapid SNP detection, molecular dynamic simulation, and QSAR analysis methods to validate clinically important genetic variants of human ABC Transporter ABCB1 (P-gp/MDR1).
Ishikawa T et al.
Pharmacology & Therapeutics, 2010
ABCB1 and ABCC1 expression in peripheral mononuclear cells is influenced by gene polymorphisms and atorvastatin treatment.
Rebecchi IM et al.
Biochemical Pharmacology, 2009
Potential impact of ABCB1 (p-glycoprotein) polymorphisms on avermectin toxicity in humans.
Macdonald N et al.
Archives of Toxicology, 2007
MDR1 haplotype frequencies in Japanese and Caucasian, and in Japanese patients with colorectal cancer and esophageal cancer.
Komoto C et al.
Drug Metabolism and Pharmacokinetics, 2006
Single nucleotide polymorphisms in human P-glycoprotein: its impact on drug delivery and disposition.
Dey S
Expert Opinion on Drug Delivery, 2006
Select a paper to view details